The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | ENCO-BRAF: encorafenib plus binimetinib in BRAF V600E-mutant NSCLC
Charles Ricordel, MD, Rennes University Hospital, Rennes, France, discusses updated efficacy and safety results from the Phase II IFCT-1904 ENCO-BRAF trial (NCT04526782), which evaluated encorafenib plus binimetinib in treatment-naive and previously treated patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC). The combination showed clinically meaningful response rates and survival outcomes in both cohorts, with a manageable safety profile consistent with previous lung cancer studies. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
